Targeting of immunoliposomes to endothelial cells expressing VCAM: a future strategy in cancer therapy.
Gosk
S
S
Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Bonn, Germany. sgosk@ruc.dk
Gottstein
C
C
Bendas
G
G
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor / Q000276:immunology / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D042783:Endothelial Cells / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D007128:Immunoglobulin Fragments / Q000008:administration & dosage* / Q000494:pharmacology; D008081:Liposomes; D051379:Mice; D011961:Receptors, Fc / Q000378:metabolism; D014407:Tumor Cells, Cultured; D019010:Vascular Cell Adhesion Molecule-1 / Q000276:immunology* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D007128:Immunoglobulin Fragments; D008081:Liposomes; D011961:Receptors, Fc; D019010:Vascular Cell Adhesion Molecule-1